Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Inclusion Criteria

• •Oncologist or gynecologist.
• •Responsible for treating ≥4-10 (depending on country) ABC/MBC patients who meet the eligibility criteria.
• •Agrees to participate in the study and complete the case report forms (CRFs) within the data collection period.
• •HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
• •Received palbociclib as a first line therapy.
• •No prior or current enrolment in an interventional clinical trial for ABC/MBC.
• •Minimum of six months of follow up data since palbociclib initiation.